Cargando…
Commentary: how will interventional oncology navigate the “valleys of death” for new medical devices?
Whereas clinical trials of cancer drugs have methodological standards and conventional primary endpoints, these are not necessarily applicable to the clinical development of loco-regional treatments and new medical devices. The current challenge is to generate high-level clinical evidence for loco-r...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Institute of Radiology.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965466/ https://www.ncbi.nlm.nih.gov/pubmed/29172678 http://dx.doi.org/10.1259/bjr.20170643 |
_version_ | 1783325363238076416 |
---|---|
author | Sharma, Ricky A Fumi, Lucio Audisio, Riccardo A Denys, Alban Wood, Bradford J Pignatti, Francesco |
author_facet | Sharma, Ricky A Fumi, Lucio Audisio, Riccardo A Denys, Alban Wood, Bradford J Pignatti, Francesco |
author_sort | Sharma, Ricky A |
collection | PubMed |
description | Whereas clinical trials of cancer drugs have methodological standards and conventional primary endpoints, these are not necessarily applicable to the clinical development of loco-regional treatments and new medical devices. The current challenge is to generate high-level clinical evidence for loco-regional treatments to define the benefits for patients. In this article, we argue that, to generate convincing evidence of clinical efficacy and safety, the collective coherence of the entire data package is often more important than the primary endpoint of one clinical trial. We also propose that, when a comprehensive clinical data package is not feasible, limited clinical data can be supplemented with other types of evidence. Emerging life science companies often define the “valley of death” after securing initial investment to translate an early medical device concept to a development stage that is attractive to funders. Unfortunately for this industry, there is a second “valley of death” if the focus and goal is only regulatory approval, to the neglect of clinical acceptance and reimbursement. For the emerging specialism of interventional oncology, it is critical to plan a clear line of sight for each new medical device to avoid the valleys of death and to demonstrate the clinical benefit. Increased international guidance to establish realistic yet convincing standards in this area may avoid attrition of potentially beneficial devices and therapeutic procedures in the valleys of death. |
format | Online Article Text |
id | pubmed-5965466 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | The British Institute of Radiology. |
record_format | MEDLINE/PubMed |
spelling | pubmed-59654662019-03-01 Commentary: how will interventional oncology navigate the “valleys of death” for new medical devices? Sharma, Ricky A Fumi, Lucio Audisio, Riccardo A Denys, Alban Wood, Bradford J Pignatti, Francesco Br J Radiol Commentary Whereas clinical trials of cancer drugs have methodological standards and conventional primary endpoints, these are not necessarily applicable to the clinical development of loco-regional treatments and new medical devices. The current challenge is to generate high-level clinical evidence for loco-regional treatments to define the benefits for patients. In this article, we argue that, to generate convincing evidence of clinical efficacy and safety, the collective coherence of the entire data package is often more important than the primary endpoint of one clinical trial. We also propose that, when a comprehensive clinical data package is not feasible, limited clinical data can be supplemented with other types of evidence. Emerging life science companies often define the “valley of death” after securing initial investment to translate an early medical device concept to a development stage that is attractive to funders. Unfortunately for this industry, there is a second “valley of death” if the focus and goal is only regulatory approval, to the neglect of clinical acceptance and reimbursement. For the emerging specialism of interventional oncology, it is critical to plan a clear line of sight for each new medical device to avoid the valleys of death and to demonstrate the clinical benefit. Increased international guidance to establish realistic yet convincing standards in this area may avoid attrition of potentially beneficial devices and therapeutic procedures in the valleys of death. The British Institute of Radiology. 2018-03 2018-01-19 /pmc/articles/PMC5965466/ /pubmed/29172678 http://dx.doi.org/10.1259/bjr.20170643 Text en © 2018 The Authors. Published by the British Institute of Radiology http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 Unported License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Commentary Sharma, Ricky A Fumi, Lucio Audisio, Riccardo A Denys, Alban Wood, Bradford J Pignatti, Francesco Commentary: how will interventional oncology navigate the “valleys of death” for new medical devices? |
title | Commentary: how will interventional oncology navigate the “valleys of death” for new medical devices? |
title_full | Commentary: how will interventional oncology navigate the “valleys of death” for new medical devices? |
title_fullStr | Commentary: how will interventional oncology navigate the “valleys of death” for new medical devices? |
title_full_unstemmed | Commentary: how will interventional oncology navigate the “valleys of death” for new medical devices? |
title_short | Commentary: how will interventional oncology navigate the “valleys of death” for new medical devices? |
title_sort | commentary: how will interventional oncology navigate the “valleys of death” for new medical devices? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965466/ https://www.ncbi.nlm.nih.gov/pubmed/29172678 http://dx.doi.org/10.1259/bjr.20170643 |
work_keys_str_mv | AT sharmarickya commentaryhowwillinterventionaloncologynavigatethevalleysofdeathfornewmedicaldevices AT fumilucio commentaryhowwillinterventionaloncologynavigatethevalleysofdeathfornewmedicaldevices AT audisioriccardoa commentaryhowwillinterventionaloncologynavigatethevalleysofdeathfornewmedicaldevices AT denysalban commentaryhowwillinterventionaloncologynavigatethevalleysofdeathfornewmedicaldevices AT woodbradfordj commentaryhowwillinterventionaloncologynavigatethevalleysofdeathfornewmedicaldevices AT pignattifrancesco commentaryhowwillinterventionaloncologynavigatethevalleysofdeathfornewmedicaldevices |